Glamorous AI

London, United Kingdom Founded: 2020 • Age: 6 yrs Acquired By X-Chem
Preclinical studies for biopharma drug discovery are conducted.

About Glamorous AI

Glamorous AI is a Healthcare company based in London (United Kingdom) founded in 2020, and was acquired by X-Chem in October 2021. Preclinical studies for biopharma drug discovery are conducted. Glamorous AI offers products and services including DEL Screening, ReadiDEL, ReadiBLOX, ArtemisAI, and HITMiner. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified.

Company details

Glamorous AI was founded in 2020 and is based in London, United Kingdom. Operations focus on the biopharma sector, where preclinical studies are conducted to support drug discovery processes. Services include analysis and testing in early-stage research, aiding pharmaceutical companies in development pipelines. The company maintains a domain at glamorous.ai for its digital presence.

  • Headquarters London, United Kingdom
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website glamorous.ai
  • Social LinkedIn X
  • Acquired by X-Chem (Oct 2021)
Key Metrics

Products & Services of Glamorous AI

Glamorous AI offers a comprehensive portfolio of products and services, including DEL Screening, ReadiDEL, ReadiBLOX, ArtemisAI, and HITMiner.

DEL Screening
Drug Discovery Service

Screening platform for identifying small molecule hits using DNA libraries.

ReadiDEL
Library Product

Pre-built library for rapid drug discovery applications.

ReadiBLOX
Chemistry Tool

Modular blocks for custom medicinal chemistry synthesis.

ArtemisAI
AI Platform

AI tool for analyzing molecular interactions in drug discovery.

HITMiner
Data Analysis Tool

Platform for mapping compounds and expanding hits in research.

Investors in Glamorous AI

Glamorous AI has secured backing from 1 investor. Prominent investors backing the company include X-Chem.

All
InvestorDescriptionFounded YearDomainLocation
Small molecule drug discovery platform is provided to researchers.
2009x-chemrx.comWaltham, United States
Premium access

Investor details for Glamorous AI

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Glamorous AI

2 dated milestones of Glamorous AI across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded Glamorous AI is founded.
  2. Exit Acquired by X-Chem.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Glamorous AI

Glamorous AI was founded in 2020.

Glamorous AI is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Glamorous AI was founded in 2020 and is based in London, United Kingdom. Operations focus on the biopharma sector, where preclinical studies are conducted to support drug discovery processes. Services include analysis and testing in early-stage research, aiding pharmaceutical companies in development pipelines. The company maintains a domain at glamorous.ai for its digital presence.

Glamorous AI offers DEL Screening, ReadiDEL, ReadiBLOX, ArtemisAI, and HITMiner.

Glamorous AI has 1 investor. Key investors include X-Chem.

Yes. Glamorous AI was acquired by X-Chem in October 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available